Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amylin, Lilly End Exenatide Tie-Up, Marking End To Litigation

This article was originally published in The Pink Sheet Daily

You may also be interested in...

Lilly Brings Non-Inferiority Data To GLP-1 Show Down

In the competitive GLP-1 market, non-inferiority data against Novo Nordisk’s market-leading Victoza will go a long way toward strengthening the commercial case for Lilly’s once-weekly GLP-1, dulaglutide, pending at FDA.

Lilly Gets Ready To Compete With Its Late-Stage Diabetes Pipeline

The Indianapolis-based pharma highlighted the Phase III results from two of its most promising pipeline candidates at ADA. The company is preparing to have four new diabetes drugs on the market by 2016, including two basal insulins, a GLP-1 agonist and a SGLT-2 inhibitor.

Lilly Discusses GLP-1 Strategy At ADA, Readies For Dulaglutide Filing

The company expects to present dulaglutide as another option for patients and expand the market instead of trying to switch patients already using GLP-1s, but analysts are interested in how it stacks up against the competition.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts